RESUMO
The aim of the present work is to determine dosimetric characteristics of commercial optically stimulated luminescence dosimeter (OSLD) to estimate equivalent dose in the patient undergoing panoramic radiography procedure. Digital panoramic unit "Instrumentarium OP200D" was used. OSL dosimeters were optically bleached before any exposure procedure. InLight™ OSL nanodosimeters were placed on the thyroid surface between the head and neck. The exposure parameters for all measurements was standard value consisted in 66â¯kV, 5â¯mA, and 14.1â¯s. Standard size field of view (FOV) scanning mode was used. Dosimeters were calibrated for the air kerma. Reported male adult equivalent doses from 21 to 45⯵Sv for each scanning for standard size field of view (FOV). Meanwhile reported female adult equivalent doses from 28 to 75⯵Sv for standard size field of view (FOV) considering all heights. The lowest equivalent dose (21⯵Sv) was observed in the male thyroid gland surface (S) position for medium height. The highest equivalent dose (75⯵Sv) was for female small height in the right parotid surface (R) position. In conclusion, the results demonstrate that OSL dosimeters are appropriate in vivo dosimetry system for dental panoramic dose measurements.
Assuntos
Dosimetria por Luminescência Estimulada Opticamente/instrumentação , Radiografia Panorâmica , Adulto , Calibragem , Feminino , Humanos , Masculino , Dosimetria por Luminescência Estimulada Opticamente/normas , Dosimetria por Luminescência Estimulada Opticamente/estatística & dados numéricos , Glândula Parótida/efeitos da radiação , Imagens de Fantasmas , Doses de Radiação , Dosímetros de Radiação , Radiografia Panorâmica/normas , Radiografia Panorâmica/estatística & dados numéricos , Reprodutibilidade dos Testes , Glândula Tireoide/efeitos da radiaçãoRESUMO
1. Human leucocyte AB antigens were determined by means of a lymphocyte toxicity test in 84 patients with essential hypertension and in 1000 blood donors. 2. The prevalence of HLA B8 was 16.4% in hypertensive patients and 8.9% in controls (P = 0.07). 3. The prevalence of HLA B12 was 34.5% in hypertensive patients and 26.9% in the control group (N.S.). In WHO stage III hypertension HLA B12 was found in six out of 10 patients. 4. The prevalence of HLA B15 was 1.2% in hypertensive patients and 6.4% in controls (P less than 0.05). 5. In view of a previous report of HLA antigens in Spanish diabetic population, this study does not support the suggestion of a genetic and possibly HLA-linked connection between essential hypertension and diabetes mellitus among the Spanish population. 6. A positive family history of hypertension tended to be more common in those patients with essential hypertension associated with HLA B8.
